Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUSA-081 (Reteplase) for Dysfunctional CVADs
NCT03594175Phase 3Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Feb 2020
- Primary completion
- Jun 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of reteplase in central venous catheter occlusion (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Percentage of Participants with Treatment Success Following a Single Instillation of Study Drug with a Dwell Time Up to 90 Min. Started Feb 2020; status: terminated.
02
Drugs
reteplase
03
Conditions
central venous catheter occlusion
Beyond the preview
Go deeper on NCT03594175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594175.